Comparative Pharmacology
Head-to-head clinical analysis: GLUCAMIDE versus GLYNASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLUCAMIDE versus GLYNASE.
GLUCAMIDE vs GLYNASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucamide (glyburide) is a sulfonylurea that stimulates insulin secretion from pancreatic beta cells by binding to the sulfonylurea receptor (SUR1) on the ATP-sensitive potassium channel (K-ATP), leading to membrane depolarization, calcium influx, and exocytosis of insulin. It may also increase peripheral insulin sensitivity and reduce hepatic glucose production.
Sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels, leading to membrane depolarization and calcium influx.
50 mg orally twice daily, increased to 100 mg twice daily after 4 weeks if tolerated
Initial dose 2.5-5 mg orally once daily with breakfast. Titrate by 2.5-5 mg weekly. Maximum dose 20 mg daily. Divided doses twice daily may be used for doses >10 mg.
None Documented
None Documented
Terminal elimination half-life is 6-8 hours in patients with normal renal function; extends to 12-18 hours in moderate renal impairment (CrCl 30-60 mL/min) and up to 24-36 hours in severe renal impairment (CrCl <30 mL/min); clinical context: duration of hypoglycemic effect correlates with half-life in renal impairment.
Terminal elimination half-life: 10-16 hours; clinical context: correlates with duration of glucose-lowering effect, prolonged in renal impairment.
Primarily renal excretion of unchanged drug (70-80%) and glucuronide conjugate (10-15%); biliary/fecal excretion accounts for 5-10%.
Renal: approximately 50% as metabolites and unchanged drug; fecal/biliary: minor (less than 5% as unchanged drug).
Category C
Category C
Sulfonylurea Antidiabetic
Sulfonylurea Antidiabetic